Epizyme (EPZM) has entered into a collaboration agreement with Foundation Medicine FMI) to support patient identification and enrollment for Epizyme's ongoing Phase 2 clinical trial of tazemetostat in patients with non-Hodgkin lymphoma. Foundation Medicine's SmartTrials Precision Enrollment Program and FoundationOne Heme panel will assist in identifying a population of individuals with NHL who harbor EZH2 mutations and constitute specific cohorts in the Epizyme trial. Tazemetostat is Epizyme's oral, first-in-class EZH2 inhibitor being investigated in multiple ongoing clinical trials. Early clinical data suggest tazemetostat has encouraging clinical activity and a favorable safety profile in patients with relapsed and refractory NHL.